Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> MutationCaroline Robert, Paolo A. Ascierto, Georgina V. Long et al.|New England Journal of Medicine|2014Cited by 5.3k
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> TrialEric F. Morand, Shalabh Singhal, Nikolay Delev et al.|Arthritis & Rheumatology|2022Cited by 246
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanomaGeorgina V. Long, Caroline Robert, Victoria Atkinson et al.|Journal of Translational Medicine|2015Cited by 53